# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!


Pancreatic cancer 4

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 1-6 of 6 results.
Mutation of K-RAS, CDKN2A, SMAD4 and TP53 in Pancreatic Cancer: Role of Liquid Biopsy in Preoperative Diagnosis
Status: Recruiting
Last Changed: Jan 25, 2019
First Received: May 15, 2018
Disease(s): Pancreatic Cancer
Intervention(s): Liquid Biopsy
Locations: St Vincent university Hospital, Dublin, Ireland
Policlinico Universitario Agostino Gemelli, Roma, Italy
AOU Sant'Andrea - UOC Chirurgia Generale, Roma, Italy
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
Status: Recruiting
Last Changed: Mar 19, 2019
First Received: May 15, 2017
Disease(s): Pancreatic Cancer
Intervention(s): Cyclophosphamide, GVAX, Pembrolizumab, IMC-CS4
Locations: Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors
Status: Recruiting
Last Changed: Sep 04, 2019
First Received: Feb 27, 2017
Disease(s): Lung Cancer Squamous Cell, Solid Tumors, Head & Neck Cancer, Pancreatic Cancer
Intervention(s): Palbociclib, Gedatolisib
Locations: Massachusetts General Hospital, Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
Status: Recruiting
Last Changed: Aug 13, 2018
First Received: Jul 13, 2015
Disease(s): Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma, Pancreatic Adenocarcinoma, Recurrent Gallbladder Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Stage III Pancreatic Cancer, Stage IIIA Gallbladder Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Gallbladder Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Gallbladder Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Pancreatic Cancer, Unresectable Gallbladder Carcinoma, Unresectable Pancreatic Cancer
Intervention(s): Cisplatin, Docetaxel, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Pharmacological Study, Recombinant EphB4-HSA Fusion Protein
Locations: USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
Status: Recruiting
Last Changed: Oct 04, 2019
First Received: Feb 21, 2019
Disease(s): Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced or Metastatic Solid Tumors, Prostate Carcinoma, MSI-H, Mismatch Repair Deficiency, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Intrahepatic Cholangiocarcinoma
Intervention(s): XmAb®22841, Pembrolizumab (Keytruda®)
Locations: Emory University, Atlanta, Georgia, United States
Karmanos Cancer Institute, Detroit, Michigan, United States
Mary Crowley Cancer Research - Medical City, Dallas, Texas, United States
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
University of Utah, Huntsman Cancer Hospital/University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, United States
... and 1 other locations.
Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer
Status: Not yet recruiting
Last Changed: Oct 07, 2019
First Received: Oct 07, 2019
Disease(s): Colorectal Cancer, Pancreatic Cancer
Intervention(s): KRAS peptide vaccine, Nivolumab, Ipilimumab
Locations: Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States